Exelixis Inc
$ 44.38
0.23%
16 Apr - close price
- Market Cap 11,525,872,000 USD
- Current Price $ 44.38
- High / Low $ 44.69 / 43.97
- Stock P/E 15.96
- Book Value 8.23
- EPS 2.78
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 0.36 %
- 52 Week High 49.62
- 52 Week Low 33.76
About
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Analyst Target Price
$46.83
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-10 | 2025-10-27 | 2025-07-28 | 2025-04-28 | 2025-02-04 | 2024-10-29 | 2024-08-06 | 2024-04-30 | 2024-02-06 | 2023-11-01 | 2023-08-01 | 2023-05-09 |
| Reported EPS | 0.97 | 0.78 | 0.75 | 0.62 | 0.55 | 0.4 | 0.77 | 0.2 | 0.27 | 0.1 | 0.25 | 0.12 |
| Estimated EPS | 0.8 | 0.6931 | 0.64 | 0.3666 | 0.4918 | 0.35 | 0.3 | 0.24 | 0.21 | 0.1 | 0.16 | 0.15 |
| Surprise | 0.17 | 0.0869 | 0.11 | 0.2534 | 0.0582 | 0.05 | 0.47 | -0.04 | 0.06 | 0 | 0.09 | -0.03 |
| Surprise Percentage | 21.25% | 12.5379% | 17.1875% | 69.1217% | 11.8341% | 14.2857% | 156.6667% | -16.6667% | 28.5714% | 0% | 56.25% | -20% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.68 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EXEL
2026-04-12 12:09:04
This article provides financial information for Exelixis, Inc. (BX:EX9), specifically focusing on its working capital per share. It is presented in a data overview format, likely from a financial platform like TradingView, allowing users to view the company's financial metrics over different periods.
2026-04-12 11:09:04
Exelixis, Inc. announced that its President and CEO, Michael M. Morrissey, Ph.D., will present at the 33rd Annual Cowen Health Care Conference on March 4, 2013. He will discuss the company's development plans for cabozantinib, corporate strategy, financial outlook, and provide a general business update. The presentation will be webcast live.
2026-04-10 21:39:06
Exelixis reported strong financial results for Q4 and FY 2025, with total revenues of $599 million and $2.320 billion respectively, driven by robust growth in its cabozantinib franchise. The company is poised for a significant year in 2026, anticipating key clinical readouts and further development of zanzalintinib, while reaffirming its 2026 financial guidance. Exelixis also highlighted the FDA's acceptance of the NDA for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer and continued its stock repurchase program.
2026-04-10 12:09:43
The Neuroendocrine Tumor Treatment Market is projected to reach USD 5.12 billion by 2035, growing at a CAGR of 6.1% from its 2025 valuation of USD 2.83 billion. This growth is driven by advancements in diagnostics and therapeutics, a shift towards targeted therapies and biologics, and increasing focus on early diagnosis. North America is expected to hold the largest market share, while Asia Pacific anticipates the largest revenue share due to improving healthcare infrastructure and rising awareness.
2026-04-08 06:10:43
Exelixis (EXEL) has seen several Wall Street analysts raise their 2026 earnings estimates due to improved business expectations and the potential of its zanzalintinib pipeline in metastatic colorectal cancer. While these upgraded forecasts support confidence in near-term execution and diversification away from its cabozantinib franchise, the company still faces concentration and pricing risks related to its primary revenue stream. Investors are encouraged to consider multiple viewpoints and conduct thorough research on the company's financial health and future prospects.
2026-04-03 09:49:50
Nisa Investment Advisors LLC significantly increased its stake in Exelixis, Inc. by 692.3% in Q4, now holding 140,446 shares valued at $6.16 million. Exelixis reported strong Q4 earnings, beating EPS estimates, though revenue slightly missed. Despite insider selling, institutional ownership remains high, and analysts have a consensus "Hold" rating with a target price of $46.94.
